Therefore, we need to identify the key biomarkers of immune heterogeneity and further dissect the biological mechanisms underlying the immunological resistance in order to develop novel, tailored treatment strategies to enhance immunotherapy efficacy in treating HR+/HER2– breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.